New Sonoma Pharma (SNOA) director granted 10,000 stock options

Rhea-AI Filing Summary

Sonoma Pharmaceuticals director Vanessa Jacoby reported an initial equity grant tied to her board appointment. She beneficially owns stock options giving her the right to buy 10,000 shares of Sonoma Pharmaceuticals common stock.

The options were granted on her appointment date and vest in three equal parts over three years. One-third vests on the first anniversary of the grant date, another third on the second anniversary, and the final third on the third anniversary, or earlier if there is a change in control. The options become exercisable starting in 2027 and expire in 2036 if not exercised.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jacoby Vanessa

(Last) (First) (Middle)

C/O SONOMA PHARMACEUTICALS, INC.

5445 CONESTOGA COURT, SUITE 150

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/28/2026

3. Issuer Name and Ticker or Trading Symbol
Sonoma Pharmaceuticals, Inc. [ SNOA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	01/28/2027	01/28/2036	Common Stock	10,000(1)	$10,000	D

Explanation of Responses:

1. The Issuer granted the options as an initial grant due to Ms. Jacoby's appointment to the Board of Directors of the Issuer. The options vest in three equal tranches over a period of three years with the first tranche vesting on the first anniversary of the grant date, the second tranche vesting on the second anniversary of the grant date, and the third tranche vesting on the third anniversary of the grant date, or upon change in control.

	/s/ Amy Trombly as attorney-in-fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Sonoma Pharmaceuticals (SNOA) Form 3 for Vanessa Jacoby report?

The Form 3 reports that director Vanessa Jacoby beneficially owns stock options for 10,000 shares of Sonoma Pharmaceuticals common stock. These options were granted as an initial equity award in connection with her appointment to the company’s Board of Directors.

How many Sonoma Pharmaceuticals (SNOA) options were granted to Vanessa Jacoby?

Vanessa Jacoby was granted stock options covering 10,000 shares of Sonoma Pharmaceuticals common stock. This grant represents her initial equity award as a new director and is reported as directly owned on her Form 3 insider ownership statement.

What is the vesting schedule of Vanessa Jacoby’s SNOA stock options?

The stock options granted to Vanessa Jacoby vest in three equal tranches over three years. One-third vests on each of the first, second, and third anniversaries of the 01/28/2026 grant date, or earlier upon a change in control of the company.

When do Vanessa Jacoby’s Sonoma Pharmaceuticals stock options become exercisable and expire?

The reporting shows Jacoby’s stock option becomes exercisable starting on 01/28/2027 and expires on 01/28/2036. This provides a roughly nine-year exercise window after first exercisability, assuming continued service and satisfaction of the vesting conditions.

Is Vanessa Jacoby’s ownership of Sonoma Pharmaceuticals (SNOA) options direct or indirect?

The Form 3 classifies Vanessa Jacoby’s ownership of the 10,000 stock options as direct (D). No trust, partnership, or other intermediary entity is listed in the nature of ownership field, and the filing includes no disclaimer of beneficial ownership.

Why did Sonoma Pharmaceuticals grant stock options to Vanessa Jacoby?

The options were granted as an initial grant due to Ms. Jacoby’s appointment to the Board of Directors. This type of equity award is intended to align a director’s economic interests with those of shareholders over the multi‑year vesting period.